timothy sykes logo
TEM Stock Rallies As Earnings Beat Fuels AI Healthcare Hype Thumbnail
G Google News

TEM Stock Rallies As Earnings Beat Fuels AI Healthcare Hype

ELLIS HOBBS•UPDATED AUG. 20, 2026, 12:33 PM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Tempus AI Inc. stocks have been trading up by 9.91 percent amid heightened optimism over its latest AI healthcare breakthroughs.

Key Takeaways

  • Tempus AI (TEM) posted Q2 revenue slightly ahead of Wall Street and raised full-year guidance to about $1.6B, with gross margin jumping to 64% and net income turning positive.
  • Despite better numbers, TEM still trades well below its 2025 highs as analysts cut price targets after earlier hype, creating a gap between price and fundamentals.
  • The planned acquisition of Personalis for $16.25 per share expands TEM’s precision oncology footprint but brings scrutiny from a shareholder-rights firm over potential conflicts.
  • With hundreds of petabytes of clinical and genomic data from tens of millions of patients, Tempus AI is framed as a leading AI–healthcare data platform with a powerful moat.

Candlestick Chart

Live Update At 12:32:50 EDT: On Thursday, August 20, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 9.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tempus AI is finally putting real numbers behind the AI story, and traders are reacting. TEM guided full-year revenue to roughly $1.6B after Q2 revenue came in modestly above consensus. That’s not a blowout, but it shows the demand story is real, not just hype on a slide deck.

Margins are where the shift really shows. Gross margin has expanded to 64%, up in a range that starts to look like a software or data platform, not a low-margin lab business. At the same time, TEM flipped to positive net income this quarter. For an AI–healthcare name that has been burning cash for years, that’s a clear inflection.

The chart backs up the turnaround. From late July to late August, TEM ripped from the low-$40s to the high-$60s, with the latest close around $67.36 after a strong intraday range up to $68.96. Intraday 5‑minute candles show steady dip-buying from the low-$60s premarket into the high-$60s by midday — classic trend day behavior.

More Breaking News

Under the hood, though, TEM is still aggressive. The latest key ratios show rich valuation — price-to-sales around 6.2 and price-to-book above 20 — plus negative return-on-equity despite the new profit. For traders, this is a momentum name priced for continued execution, not a value play.

Why Traders Are Watching Tempus AI Now

TEM is in that sweet spot where the story is big, the numbers are finally catching up, and the chart is screaming momentum. The Q2 print gave traders exactly what they want to see in an AI growth name: revenue slightly ahead of expectations, full-year guidance raised to about $1.6B, and proof that scale is dropping to the bottom line with positive net income and a 64% gross margin.

Yet TEM still trades well below its 2025 highs. Analysts have been trimming price targets as the market cools on anything that looks “too expensive,” even when execution is solid. That disconnect — improving fundamentals but a stock that hasn’t reclaimed prior peaks — is where active traders live. Either the stock is setting up for a rerating, or it’s telling you that expectations were simply too high last time around.

The strategic backdrop matters here. Tempus AI sits at the intersection of AI and healthcare, running genomic diagnostics on top of a data asset measured in hundreds of petabytes across tens of millions of patients. That kind of scale is the definition of a data moat. Pharma partners license that data, and every new test TEM runs makes the platform smarter.

On top of that, TEM is pushing deeper into oncology with the planned acquisition of Personalis, a leader in minimal residual disease testing, for $16.25 per share. For the Tempus AI platform, that’s a logical bolt-on to strengthen cancer monitoring and longitudinal data. But the deal isn’t clean headline-wise: a shareholder-rights firm is probing whether Tempus AI’s existing stake and strategic relationship pressured Personalis holders into accepting a low price. Traders don’t need to predict the legal outcome — they just need to respect the headline risk.

Put it together, and TEM is a classic high-expectation growth trade: big upside if execution continues, but no room for complacency.

Conclusion

For active traders, Tempus AI is a live case study in how hype transitions into hard numbers. TEM has moved from “AI story stock” to a business with roughly $1.6B in guided revenue, a 64% gross margin, and a fresh turn into positive net income. The multi-week run from the low-$40s to the high-$60s shows how quickly sentiment can swing when the tape and the fundamentals finally line up.

At the same time, TEM’s financial profile still screams high risk, high reward. Returns on equity remain negative on a trailing basis, valuation multiples are rich, and the balance sheet shows a levered, growth-first strategy. The Personalis acquisition adds strategic depth to Tempus AI’s precision oncology stack but also layers in regulatory and governance noise that can spark sharp, news-driven candles in either direction.

For traders who study price action, the current setup in TEM is straightforward: strong uptrend, big story, rising fundamentals, and crowded expectations. That’s a mix that demands tight risk controls and clear trade plans, not blind belief in the AI narrative. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.”. As Tim Sykes loves to remind his students, “The market doesn’t care about your opinion, only your preparation and your rules.” Tempus AI is giving prepared traders plenty to work with — but the rules still matter most.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”